Omeros Corporation’s hopes of launching its investigational product, narsoplimab, as a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were reinforced by positive pivotal data presented a this year’s European Hematology Association meeting.
The virtual presentation on 11 June showed good organ function improvement in high-risk patients treated with the product, and underscored...